Alzheimer Disease

Disease State Hub

Podcasts

Alzheimer Disease

The Association of Flavonols on Alzheimer Dementia Risk

05/19/2022

In this podcast, Thomas Holland, MD, from Rush University, answers our questions about his team's latest research on the effect of flavonols on the risk for Alzheimer dementia, as well as his other research...

05/19/2022

Geriatrics

ANA Investigates Biomarkers for Alzheimer Disease

08/19/2020

David Holtzman, MD, talks about the established biomarkers for Alzheimer disease, potential biomarkers being investigated, and how long it may take for these biomarker tests to make it to the bedside.

08/19/2020

Alzheimer Disease

Erin Sundermann, PhD, on Redefining the Norms and Cut Points for Diagnosing MCI Among Men vs Women

01/21/2020

In this podcast, Erin Sundermann, PhD, discusses her research on sex-specific norms and cut points for verbal memory tests and how redefining the criteria for men vs women may improve diagnostic accuracy of...

01/21/2020

Alzheimer Disease

Shane Liddelow, PhD, on Astrocytes Induced by Activated Microglia

08/12/2019

In this podcast, Shane Liddelow, PhD, from NYU Langone Health, discusses his latest research on astrocytes—a topic he also spoke about at the Alzheimer's Association International Conference 2019.

08/12/2019

Alzheimer Disease

David Llewellyn, MD, on the Bias in Cognitive Assessments

02/04/2019

Dr David Llewellyn from the University of Exeter Medical School answers our questions about his research on dementia misclassification when using brief cognitive assessments.

02/04/2019

Neurology

Basem Ratrout, MD, on Evaluating and Diagnosing Dementia

02/01/2017

Basem Ratrout, MD, talks about dementia and how primary care providers can evaluate, diagnose, and refer their patients.

02/01/2017

For more on the etiology of Alzheimer disease content, visit our Clinical Update page

The most common type of dementia, Alzheimer disease is a progressive disease that generally begins with mild memory loss and involves parts of the brain that control thought, memory, and language.

For more Alzheimer Disease content, visit the Clinical Insights page

Brain changes may begin 10+ years before symptoms appear. These changes include buildup of proteins that form amyloid plaques and tau tangles. This causes healthy neurons to stop functioning, lose connections with other neurons, and die.

For more neurology content, visit the Resource Center

occupational therapist, neurologist, geriatrician, psychiatrist, primary care physicians, geropsychologist

For more dementia content, visit the Disease State Hub

Memory loss that disrupts daily life
Difficulty completing familiar tasks at home, at work, or at leisure
Worsening judgment
Misplacing items & failure to retrace steps
Changes in mood, personality, or behavior

For more imaging content, visit the Resource Center

There is no single test to determine AD, but testing options include: computed tomography scan, magnetic resonance imaging, positron emission tomography scan, cerebrospinal fluid analysis, neurological examination

For more neurological diseases content, visit the Disease State Hub

Examples of cognitive, functional, and behavioral tests include: Ascertain Dementia 8, Activities Questionnaire, Mini-Cog Mini-Mental State Examination, Montreal Cognitive Assessment, Neuropsychiatric Inventory Questionnaire

For more traumatic brain injury content, visit the Resource Center

Age
Family history
Genetics
Mild cognitive impairment
Modifiable risk factors, like obesity, high cholesterol, poorly controlled type 2 diabetes

For more polls and quizzes, visit the interactive features page

An estimated 6.7 million Americans aged 65 years or older are living with AD (73% are aged 75 years or older)

For more patient education content, visit the Resource Center

By 2025, the number of people aged 65 or older with AD is projected to reach 7.2 million — a 7% increase from 2023.

September 2023

Current Issue

September 2023

Volume 63

Issue 9

Sources

CDC.gov
2023 Alzheimer's Facts and Figures